
Opinion|Videos|July 23, 2025
Epidemiology Associated With Alopecia Areata
Key Takeaways
- Alopecia areata is a chronic autoimmune disorder causing non-scarring hair loss due to immune system attacks on hair follicles.
- Breakdown of immune privilege in hair follicles leads to infiltration by cytotoxic T cells, particularly CD8+ T cells.
Panelists discuss how the epidemiology of alopecia areata (AA) varies across different patient populations, with certain forms of the disease being more prevalent in specific groups.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Ungar: What is the epidemiology of AA, and can you describe the different forms of AA that you see in your practice?
- Is there a population in which AA occurs more frequently based on your clinical experience?
- Is there a population in which AA occurs more frequently based on your clinical experience?
Advertisement
Related to this article

Employer-mandated enrollment in a high-deductible health plan did not reduce use of oral targeted anticancer medications among patients commercially insured between 2007 and 2021.

We identify the health system characteristics associated with greater or lesser documentation of patients’ social determinants of health.

MA-to-MA switching among dually eligible beneficiaries rose sharply from 2016 to 2022, AJMC study author Grace Mackleby, PhD, found.

This moves the noncovalent BTK inhibitor into the first-line setting for certain adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.

CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to succeed.

This week in health equity and access: PMOS diagnosis, HIV lung cancer screening, transplant access, atopic dermatitis care, and value-based oncology.

Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
Advertisement
Advertisement
Trending on AJMC
1
Pharmacists Bridge the Vaccine Trust Gap as COVID-19 Persists
2
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
3
FDA Approves Pirtobrutinib for Untreated CLL/SLL Without 17p Deletion
4
Who Recommends COVID-19 Vaccines Without ACIP?
5

